Sociodemographic, Clinical, and Laboratory Characteristics in Patients With Clinically Manifest Coronary Heart Disease and in the Sub-population with History of Gout.

a<p>median, 25^th and 75^th percentile cut-point.</p>b<p>CKD-Epi = Chronic Kidney Disease Epidemiology Collaboration equation.</p>c<p>based on Wilcoxon Two-Sample Test for continuous variables, Chi-Square Test for proportions.</p

Association of Uric Acid Concentrations and hs-CRP (categories, e.g. quartiles) at Baseline With Subsequent Fatal and Non-Fatal CVD Events During Follow-Up.

a<p>considered main model - beside the main factors (the variables age, gender and hospital site), the following potential confounders were included in multivariable analyses: smoking status (never, current, ex-smoker), history of myocardial infarction (yes, no), history of diabetes mellitus (yes, no), severity of CHD (number of affected epicardial vessels at baseline), intake of ACE-inhibitors (yes, no), intake of allopurinol (yes, no), HDL-cholesterol (mg/dl), LDL-cholesterol (mg/dl). Only those variables were added to the model which were significant predictors of a subsequent event at a α-level of 0.1 or which changed the parameter estimates for the main variables by more than 10% <i>(details see methods for variable selection).</i></p>b<p>adjusted for above listed variables (^a) and CKD-EPI.</p

Kaplan-Meier Estimates of Subsequent Fatal and Non-Fatal CVD Events) during Follow-Up According to Quartiles of Uric Acid at Baseline.

<p>Kaplan-Meier Estimates of Subsequent Fatal and Non-Fatal CVD Events) during Follow-Up According to Quartiles of Uric Acid at Baseline.</p

Measures of Model Accuracy With and Without Serum Uric Acid (SUA).

a<p>adjusted for age, gender and hospital site, smoking status (never, current, ex-smoker), history of myocardial infarction (yes, no), history of diabetes mellitus (yes, no), severity of CHD (number of affected epicardial vessels at baseline), intake of ACE-inhibitors (yes, no), intake of allopurinol (yes, no), HDL-cholesterol (mg/dl), LDL-cholesterol (mg/dl) (<i>model 2 of </i><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0045907#pone-0045907-t002" target="_blank"><i>table 2</i></a><i> according to variable selection criteria</i>).</p

Kaplan-Meier Estimates of Subsequent Fatal and Non-Fatal CVD Events during Follow-Up According to Quartiles of CRP at Baseline.

<p>Kaplan-Meier Estimates of Subsequent Fatal and Non-Fatal CVD Events during Follow-Up According to Quartiles of CRP at Baseline.</p

Kaplan-Meier Estimates of Subsequent Fatal and Non-Fatal CVD Events During Follow-Up According to Quartiles of IL-6 at Baseline.

<p>Kaplan-Meier Estimates of Subsequent Fatal and Non-Fatal CVD Events During Follow-Up According to Quartiles of IL-6 at Baseline.</p

Proportion of patients with “1”, “2–11”, “12–23”, and “24+” LABA containing-prescriptions in 2008, for all patients with LABA-containing prescriptions (a), asthma patients with LABA-containing prescriptions (b), COPD patients with LABA-containing prescriptions (c), and asthma and COPD patients with LABA-containing prescriptions (d) (AHC: Mondriaan–AHC, NPCRD: Mondriaan–NPCRD).

<p>Proportion of patients with “1”, “2–11”, “12–23”, and “24+” LABA containing-prescriptions in 2008, for all patients with LABA-containing prescriptions (a), asthma patients with LABA-containing prescriptions (b), COPD patients with LABA-containing prescriptions (c), and asthma and COPD patients with LABA-containing prescriptions (d) (AHC: Mondriaan–AHC, NPCRD: Mondriaan–NPCRD).</p

Main characteristics of databases.

<p>Main characteristics of databases.</p

Comparison of annual period prevalence rate (PPR) of LABA-containing prescriptions in 7 European databases stratified by age and sex for the year 2008.

<p>LABA: Long-acting beta-2-agonist.</p><p>CI: Confidence interval.</p><p>*Age group: 0–19 years</p><p>Comparison of annual period prevalence rate (PPR) of LABA-containing prescriptions in 7 European databases stratified by age and sex for the year 2008.</p